User:Mr. Ibrahem/Letrozole
Clinical data | |
---|---|
Trade names | Femara, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a698004 |
License data | |
Routes of administration | By mouth (tablets) |
Drug class | Aromatase inhibitor; Antiestrogen |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 99.9% |
Protein binding | 60%, mainly to albumin |
Metabolism | pharmacologically-inactive metabolites Bis(4-cyanophenyl)methanol and 4,4'-dicyanobenzophenone.[1] |
Elimination half-life | 2 days[1] |
Excretion | Kidneys[1] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C17H11N5 |
Molar mass | 285.310 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Letrozole, sold under the brand name Femara among others, is a medication used for breast cancer.[3] It has also be used in female infertility to bring about ovulation.[3] For breast cancer, it is only used after menopause.[2] It is taken by mouth.[3]
Common side effects include high cholesterol, hot flushes, joint pain, and swelling.[3] Other side effects may include infertility, tiredness, and osteoporosis.[3] Use in pregnancy may harm the baby.[3] It is an aromatase inhibitor.[3]
Letrozole was patented in 1986 and approved for medical use in 1996.[4] It is available as a generic medication.[5] In the United States 3 months of treatment costs about 20 USD as of 2021.[5] In the United Kingdom this amount costs the NHS about £7.[2]
References[edit]
- ^ a b c 003330 Letrozole
- ^ a b c d BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 999. ISBN 978-0857114105.
- ^ a b c d e f g h "Letrozole Monograph for Professionals". Drugs.com. Archived from the original on 10 August 2020. Retrieved 21 November 2021.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 516. ISBN 9783527607495. Archived from the original on 2016-12-20. Retrieved 2020-09-19.
- ^ a b "Letrozole Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 14 November 2016. Retrieved 21 November 2021.